Bicycle Therapeutics PLC (NAS:BCYC)
$ 25 0.26 (1.05%) Market Cap: 1.73 Bil Enterprise Value: 846.38 Mil PE Ratio: 0 PB Ratio: 2.08 GF Score: 75/100

Bicycle Therapeutics PLC at Jefferies London Healthcare Conference Transcript

Nov 17, 2022 / 08:00AM GMT
Release Date Price: $27.36 (-5.03%)
Kelly Shi
Jefferies - Analyst

Good morning, everyone. Thank you for attending Jefferies London Healthcare Conference. My name is Kelly Shi, one of the biotech analysts at Jefferies.

It is our great pleasure to host Mr. Kevin Lee, CEO of Bicycle Therapeutics. We also have Mr. Lee Kalowski, CFO; and Dr. Nick Keen, Chief Scientific Officer; and Mr. Dominic Smethurst, Chief Medical Officer, for a fireside chat. Welcome, everyone.

Questions & Answers

Kelly Shi
Jefferies - Analyst

And first, maybe would you like to give a brief introduction of the company and also discuss where do you see the application of Bicycle molecules to the broader space of drug development?

Kevin Lee
Bicycle Therapeutics plc - CEO

Hi. Thanks, Kelly. And many thanks to Jefferies for the invitation and, obviously, the audience for getting up so early this morning.

Bicycle is a company that was founded by Sir Greg Winter. Many of you all know Sir Greg Winter from his pioneering work in antibodies and peptides, and

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot